Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TULIP: TA-8995 in Mild Dyslipidaemia
NCT01970215Phase 2Completed
- Sponsor
- Xention Ltd.
- Start
- Aug 2013
- Primary completion
- Jul 2014
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of obicetrapib in dyslipidemia, sponsored by Xention Ltd.. Started Aug 2013; status: completed.
02
Drugs
obicetrapib
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT01970215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01970215.